(Q34640811)

English

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (English)

1 reference

Europe PubMed Central

3 August 2017

0 references

0 references

biological psychiatry

1 reference

based on heuristic

inferred from title

Birte Yding Glenthøj

5

object named as

Birte Glenthoj

1 reference

Europe PubMed Central

3 August 2017

object named as

Peter Falkai

2

0 references

1

object named as

Alkomiet Hasan

1 reference

Europe PubMed Central

3 August 2017

Hans-Jürgen Möller

8

object named as

Hans-Jürgen Möller

1 reference

Europe PubMed Central

3 August 2017

Jeffrey Lieberman

4

object named as

Jeffrey Lieberman

1 reference

Europe PubMed Central

3 August 2017

Wagner Farid Gattaz

6

object named as

Wagner F Gattaz

1 reference

Europe PubMed Central

3 August 2017

author name string

Thomas Wobrock

3

1 reference

Europe PubMed Central

3 August 2017

Florence Thibaut

7

1 reference

Europe PubMed Central

3 August 2017

World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia

9

1 reference

Europe PubMed Central

3 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 July 2012

1 reference

Europe PubMed Central

3 August 2017

World Journal of Biological Psychiatry

1 reference

Europe PubMed Central

3 August 2017

13

1 reference

Europe PubMed Central

3 August 2017

5

1 reference

Europe PubMed Central

3 August 2017

318-378

1 reference

Europe PubMed Central

3 August 2017

The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Is olanzapine better than haloperidol in resistant schizophrenia? A double-blind study in partial responders.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The effect of quetiapine on aggression and hostility in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Sertindole for the treatment of schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

How to grade categories of evidence.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Antipsychotic polypharmacy in schizophrenia: benefits and risks

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Pharmacological management of first-episode schizophrenia and related nonaffective psychoses

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Defining treatment refractoriness in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Prescribing patterns of antipsychotics in 13 French psychiatric hospitals

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clozapine: efficacy and safety

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Olanzapine treatment of residual positive and negative symptoms

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Structural evaluation of the prefrontal cortex in schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The pharmacology and toxicology of atypical antipsychotic agents

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clinical advantages of amisulpride in the treatment of acute schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Treatment of negative symptoms

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Evaluation of treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Management of treatment resistance in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham-controlled, randomized multicenter study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Intramuscular aripiprazole in the control of agitation.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Overview: maintenance therapy in psychiatry: I. Schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Dose response and dose equivalence of antipsychotics

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Second-generation antipsychotics and constipation: a review of the literature

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clozapine-related seizures

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Neuroleptic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Conventional antipsychotic medications for schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Combined treatment of schizophrenic psychoses with haloperidol and valproate

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clozapine plus lamotrigine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Atypical neuroleptic malignant syndrome with quetiapine: a case report and review of the literature

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Aripiprazole for schizophrenia. Systematic review

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Catatonia in psychotic patients: clinical features and treatment response

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Augmentation with pregabalin in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Catatonia: diagnosis, classification, and treatment

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Olanzapine and haloperidol in first episode psychosis: two-year data

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Antipsychotic-related QTc prolongation, torsade de pointes and sudden death

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

[Effectiveness of zotepine in therapy-refractory psychoses. An open, multicenter study in eight psychiatric clinics]

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effectiveness of second-generation antipsychotics with acute-phase schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Antipsychotic medication and seizures: a review

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clozapine alone versus clozapine and risperidone with refractory schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Psychopharmacologic treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Tardive Dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risk factors for neuroleptic malignant syndrome. A case-control study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Prolactin levels and adverse events in patients treated with risperidone.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Switching to amisulpride monotherapy for treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Electroconvulsive therapy for treating schizophrenia: a chart review of patients from two catchment areas

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Trial of aripiprazole in the treatment of first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Second-generation antipsychotics for schizophrenia: can we resolve the conflict?

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Maintenance electroconvulsive therapy: an alternative treatment for refractory schizophrenia and schizoaffective disorders

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Physical health monitoring of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Quality assessment and comparison of evidence for electroconvulsive therapy and repetitive transcranial magnetic stimulation for schizophrenia: a systematic meta-review

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Defining treatment refractoriness in schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Combination antipsychotics: pros, cons, and questions

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Extrapyramidal side-effects of antipsychotics in a randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Management of the negative symptoms of schizophrenia: new treatment options

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Do effectiveness ("real world") studies on antipsychotics tell us the real truth?

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Topiramate and psychiatric adverse events in patients with epilepsy

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Assessing QT interval prolongation and its associated risks with antipsychotics.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Neuroleptic malignant syndrome and serotonin syndrome

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Determining the optimal dose of haloperidol in first-episode psychosis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Short-term inpatient pharmacotherapy of schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Olanzapine: a review of rapid and long-acting parenteral formulations

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clozapine-related seizures: experience with 5,629 patients

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Polypharmacy with second-generation antipsychotics: a review of evidence

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Neuroleptic malignant syndrome: a review

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Antipsychotics-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clozapine in China: a review and preview of US/PRC collaboration

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone versus placebo for schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Lamotrigine--clozapine combination in refractory schizophrenia: three cases

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Olanzapine versus haloperidol treatment in first-episode psychosis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Pregabalin in the treatment of schizophrenic anxiety.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Treatment strategies for dosing the second generation antipsychotics.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Quetiapine in schizophrenia: onset of action within the first week of treatment

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Results of phase 3 of the CATIE schizophrenia trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidon

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Neuroleptic malignant syndrome associated with atypical antipsychotic drugs

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Elevation of prolactin levels by atypical antipsychotics

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Benzodiazepines and the psychopathology of catatonia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Does cognitive function improve with quetiapine in comparison to haloperidol?

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

High-dose treatment with haloperidol: the effect of dose reduction.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Intramuscular olanzapine: a review of its use in the management of acute agitation

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA).

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Combination therapy in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Benzodiazepines in the treatment of schizophrenia: a review and reappraisal

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Clozapine use in schizophrenia: findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Antipsychotic drugs and QT interval prolongation

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Beta-blocker supplementation of standard drug treatment for schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.696143

21 January 2018

Identifiers

10.3109/15622975.2012.696143

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34640811&oldid=1756304908"